Gastroprotective Agent Rebamipide Induces Cyclooxygenase-2 (COX-2) in Gastric Epithelial Cells

被引:2
|
作者
Hiroaki Murata
Yuki Yabe
Shingo Tsuji
Masahiko Tsujii
Hai Ying Fu
Kayoko Asahi
Hiroshi Eguchi
Sunao Kawano
Norio Hayashi
机构
[1] Osaka University Graduate School of Medicine,Department of Gastroenterology and Hepatology
[2] Osaka University Graduate School,Department of Clinical Laboratory Science, School of Allied Health Sciences
来源
关键词
COX-2; rebamipide; gastric epithelial cells; reporter assay;
D O I
暂无
中图分类号
学科分类号
摘要
Cyclooxyngease-2 (COX-2) is a key enzyme in prostaglandin (PG) synthesis, and COX-2 induction plays an important role in the healing of gastric ulceration. Rebamipide is a gastroprotective agent and attenuates the activity of neutrophils. A number of reports have shown that rebamipide treatment increases PG production in the gastric mucosa {in vivo}. Although its clinical significance in ulcer healing has been demonstrated, {in vitro} evidence remains to be accumulated. Non-transformed rat gastric mucosal cells (RGM1 cells) were stimulated with rebamipide. RT-PCR and Western blot analysis revealed time and dose-dependent transcriptional and translational stimulation of COX-2. PGE2 was also produced dose-dependently. However, marked COX-2 induction by rebamipide was transient and lasted less than 24 hr. COX-1 expression was unaltered by rebamipide. Reporter assay results confirmed the stimulation of Cox-2 promoter activity by rebamipide. In conclusion, this study provides {in vitro} evidence that rebamipide transcriptionally induces COX-2 and supports the rationale for its clinical use.
引用
收藏
页码:S70 / S75
相关论文
共 50 条
  • [21] The selective cyclooxygenase-2 inhibitor nimesulide induces apoptosis in pancreatic cancer cells independent of COX-2
    Eibl, G
    Reber, HA
    Wente, MN
    Hines, OJ
    PANCREAS, 2003, 26 (01) : 33 - 41
  • [22] The role of cyclooxygenase-2 (COX-2) in breast cancer, and implications of COX-2 inhibition
    Singh-Ranger, G
    Mokbel, K
    EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2002, 28 (07): : 729 - 737
  • [23] Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors
    Groesch, Sabine
    Maier, Thorsten Juergen
    Schiffmann, Susanne
    Geisslinger, Gerd
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (11): : 736 - 747
  • [24] NSAIDS REVISITED CYCLOOXYGENASE-2 (COX-2) INHIBITORS
    JENSEN, NP
    MEDICINAL CHEMISTRY RESEARCH, 1995, 5 (05) : 319 - 324
  • [25] Cyclooxygenase-2 (COX-2) enzyme inhibitors and radiotherapy
    Milas, L
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2003, 26 (04): : S66 - S69
  • [26] Cyclooxygenase-2 (Cox-2) expression and angiogenesis in glioblastoma
    Onguru, Onder
    Gamsizkan, Mehmet
    Ulutin, Cuneyt
    Gunhan, Omer
    NEUROPATHOLOGY, 2008, 28 (01) : 29 - 34
  • [27] Transcriptional regulation of cyclooxygenase-2 (COX-2) in hypoxia
    Cook-Johnson, Rebecca J.
    Peet, Dan
    Gamble, Jenny
    Cleland, Leslie
    James, Michael
    INFLAMMATION RESEARCH, 2005, 54 : S183 - S183
  • [28] Effect of glycosylation of cyclooxygenase-2 (COX-2) on homodimerization
    Vann-Victorino, Daniel DeWayne Colbert
    Cunanan, Jelaine
    Chen, Mindy
    Chan, Rena
    Hall, Randall W.
    Sevigny, Mary B.
    FASEB JOURNAL, 2017, 31
  • [29] APRICOXIB Cyclooxygenase-2 (COX-2) Inhibitor Oncolytic
    Edelman, Martin J.
    DRUGS OF THE FUTURE, 2011, 36 (07) : 503 - 509
  • [30] Expression of cyclooxygenase-2 (COX-2) in pituitary tumours
    Sokolowski, Grzegorz
    Baldys-Waligorska, Agata
    Trofimiuk, Malgorzata
    Adamek, Dariusz
    Hubalewska-Dydejczyk, Alicja
    Golkowski, Filip
    MEDICAL SCIENCE MONITOR, 2012, 18 (04): : CR252 - CR259